SELLAS Life Sciences (SLS) Assets Average (2011 - 2026)
SELLAS Life Sciences (SLS) reported Assets Average of $96.3 million for Q1 2026, up 253.98% year-over-year from $27.2 million in Q1 2025, and up 48.21% on a QoQ basis from $65.0 million in Q4 2025.
SELLAS Life Sciences (SLS) has 16 years of Assets Average data on file, last reported at $96.3 million in Q1 2026.
- Quarterly Assets Average rose 253.98% year-over-year to $96.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.3 million (up 253.98% YoY) and the FY2025 annual result came in at $48.9 million, up 281.18% from the prior year.
- Assets Average advanced to $96.3 million in Q1 2026 per SLS's latest filing, from $65.0 million in the prior quarter.
- Across five years, Assets Average topped out at $96.3 million in Q1 2026 and bottomed at $7.2 million in Q4 2023.
- The 5-year median for Assets Average is $23.9 million (2022), against an average of $30.3 million.
- The widest annual swing landed in 2023, when Assets Average slumped 69.53%; it then soared 253.98% in 2026.
- Tracing SLS's Assets Average over 5 years: stood at $23.5 million in 2022, then tumbled by 69.53% to $7.2 million in 2023, then surged by 221.13% to $23.0 million in 2024, then surged by 182.78% to $65.0 million in 2025, then jumped by 48.21% to $96.3 million in 2026.
- Per Business Quant, the three latest SLS Assets Average figures stand at $96.3 million (Q1 2026), $65.0 million (Q4 2025), and $41.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 96.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.26 Mn |
| Dec 31, 2025 | 64.95 Mn |
| Sep 30, 2025 | 41.93 Mn |
| Jun 30, 2025 | 33.63 Mn |
| Mar 31, 2025 | 27.19 Mn |
| Dec 31, 2024 | 22.97 Mn |
| Sep 30, 2024 | 20.81 Mn |
| Jun 30, 2024 | 19.78 Mn |
| Mar 31, 2024 | 15.33 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | 13.33 Mn |
| Jun 30, 2023 | 23.84 Mn |
| Mar 31, 2023 | 25.02 Mn |
| Dec 31, 2022 | 23.47 Mn |
| Sep 30, 2022 | 29.11 Mn |
| Jun 30, 2022 | 26.82 Mn |
| Mar 31, 2022 | 23.85 Mn |
| Dec 31, 2021 | 32.11 Mn |
| Sep 30, 2021 | 40.79 Mn |
| Jun 30, 2021 | 42.10 Mn |
| Mar 31, 2021 | 43.31 Mn |
| Dec 31, 2020 | 32.28 Mn |
| Sep 30, 2020 | 16.51 Mn |
| Jun 30, 2020 | 15.77 Mn |
| Mar 31, 2020 | 16.82 Mn |
| Dec 31, 2019 | 19.05 Mn |
| Sep 30, 2019 | 23.26 Mn |
| Jun 30, 2019 | 19.98 Mn |
| Mar 31, 2019 | 15.92 Mn |
| Dec 31, 2018 | 27.69 Mn |
| Sep 30, 2018 | 35.22 Mn |
| Jun 30, 2018 | 32.73 Mn |
| Mar 31, 2018 | 33.51 Mn |
| Dec 31, 2017 | 41.56 Mn |
| Sep 30, 2017 | 55.07 Mn |
| Jun 30, 2017 | 65.44 Mn |
| Mar 31, 2017 | 38.38 Mn |
| Dec 31, 2016 | 39.63 Mn |
| Sep 30, 2016 | 73.31 Mn |
| Jun 30, 2016 | 70.07 Mn |
| Mar 31, 2016 | 74.25 Mn |
| Dec 31, 2015 | 82.41 Mn |
| Sep 30, 2015 | 92.32 Mn |
| Jun 30, 2015 | 105.29 Mn |
| Mar 31, 2015 | 94.55 Mn |
| Dec 31, 2014 | 79.99 Mn |
| Sep 30, 2014 | 79.88 Mn |
| Jun 30, 2014 | 86.28 Mn |
| Mar 31, 2014 | 90.13 Mn |
| Dec 31, 2013 | 89.62 Mn |
| Sep 30, 2013 | 76.63 Mn |
| Jun 30, 2013 | 61.73 Mn |
| Mar 31, 2013 | 58.22 Mn |
| Dec 31, 2012 | 45.09 Mn |
| Mar 31, 2012 | 29.59 Mn |
| Dec 31, 2011 | 30.65 Mn |
| Sep 30, 2011 | 31.34 Mn |